Zealand Pharma and UniQuest join forces to develop venom-derived peptides treating gastrointestinal illnesses: 3 things to know

Copenhagen, Denmark-based Zealand Pharma and UniQuest, the commercialization company of The University of Queensland in Australia, are collaborating to develop new drug candidates inspired by venoms to treat gastrointestinal diseases.

Here are three things to know:

1. Zealand Pharma has a proprietary peptide technology. UQ's Institute for Molecular Bioscience's has a large collection of animal venoms, and IMB researchers have extensive experience in identifying novel bioactive peptides from venoms.

2. Zealand and the university researchers will work together to identify venom-derived peptides that act against a range of drug targets to treat gastrointestinal and metabolic diseases. Zealand will then further develop these novel drug candidates.

3. UQ is ranked in the top 20 universities for life sciences research in the world. The collaboration will also draw on expertise from Flinders University in South Australia.

More articles on gastroenterology:

GI leader to know: Dr. Atul Vachhani of Santa Maria Gastroenterology

Dr. Khalid Naseer joins Crossroads Specialty Clinic — 3 insights

Want to improve outcomes and save money? Implement an enhanced recovery protocol

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast